Myocardial Infarction Market

DelveInsight’s ‘Myocardial Infraction (MI) – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Myocardial Infraction (MI), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Myocardial Infraction (MI) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Myocardial Infarction symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Myocardial Infraction (MI) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Myocardial Infraction (MI) Disease Understanding and Treatment Algorithm

Myocardial Infraction (MI) Overview

Myocardial infarction (MI) refers to ischemic necrosis of myocardial tissue. The most common underlying cause of Myocardial Infarction is coronary artery disease. From a pathologic perspective, Myocardial Infarction is defined as cardiomyocyte death caused by an ischemic insult.


MI is a consequence of an imbalance between oxygen supply and demand. As plaques accumulate gradually, a severe atherosclerotic disease resulting in ≥75% luminal narrowing does not cause a reduction in blood flow at rest. However, when myocardial demand is increased (due to exercise, tachyarrhythmia, etc.), the flow restriction precludes an increase in oxygen supply, resulting in ischemia and causing angina pectoris.


In the vast majority of cases, Myocardial Infarction results from coronary atherosclerotic disease complicated by superimposed thrombosis. Although most patients with Myocardial Infarction have significant obstructive coronary disease, occasionally plaque rupture and ulceration can occur in the absence of an angiographically obstructive lesion.


The initial evaluation of a patient with a suspected AMI should include a focused clinical history, physical examination, electrocardiography, cardiac markers, and a chest radiograph. Diagnosis is based on typical clinical features, ECG findings, and elevation of cardiac biomarkers. Definitive diagnosis requires cardiac catheterization, which serves both diagnostic and therapeutic purposes.


The goals of initial treatment of an Myocardial Infarction are relief of pain, immediate identification of ST changes via 12-lead EKG, initiation of reperfusion (if the patient is a candidate), and assessment and treatment of hemodynamic abnormalities. Pain relief is best achieved with oxygen, nitroglycerin, and morphine sulfate. Patients with ST-segment elevation or a new LBBB with symptoms for 12 h or less are candidates for reperfusion therapy. Further treatment of an Myocardial Infarction may be separated into two pathways depending on whether or not the patient has a STEMI or an NSTEMI.


Myocardial Infraction (MI) Diagnosis and Treatment

It covers the details of conventional and current medical therapies, and diagnosis available in the Myocardial Infraction (MI) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Myocardial Infraction (MI) market report gives a thorough understanding of Myocardial Infarction symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Myocardial Infarction symptoms of treatment algorithms and treatment guidelines for Myocardial Infarction symptoms in the US, Europe, and Japan.

Myocardial Infraction (MI) Epidemiology

The epidemiology division’s Myocardial Infraction (MI) symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Myocardial Infraction (MI) epidemiology segmented as Prevalent Cases of Myocardial Infarction, Gender-specific cases of Myocardial Infraction (MI), Type-specific cases of Myocardial Infraction (MI). The report includes the Prevalent scenario of Myocardial Infarction symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Myocardial Infraction (MI) Epidemiology

The epidemiology segment also provides the Myocardial Infraction (MI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM Prevalent cases of Myocardial Infraction (MI) were 13,123 in 2020.

Myocardial Infraction (MI) Drug Chapters

The drug chapter segment of the Myocardial Infraction (MI) report encloses the detailed analysis of Myocardial Infarction marketed drugs and late stage (Phase-II and Phase-III) pipeline drugs. It also helps understand the Myocardial Infraction (MI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


With multiple etiologies, treatment is focused symptomatic relief, including better sphincter control. Guidelines have been set forth regarding the optimal FI classification and management, but they must be taken in the context of the situation and cannot be used in every circumstance.

Products detail in the report…


Myocardial Infraction (MI) Emerging Drugs


Empagliflozin (Boehringer Ingelheim and Eli Lilly and Company) is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. According to the company, Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, increasing the amount of glucose excreted in the urine. It has a relatively long duration of action requiring only once-daily dosing. The drug has also received Fast Track designation for the development of Jardiance (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction, which will give the advantage to occupy good market share.

Products detail in the report…

Myocardial Infraction (MI) Market Outlook

The Myocardial Infraction (MI) market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Myocardial Infraction (MI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a thorough detail of Myocardial Infraction (MI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Myocardial Infraction (MI) market in 7MM is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the Myocardial Infraction (MI) market in 7MM. The market size of Myocardial Infarction in the seven major markets was found to be USD 11,038 million in 2020 and market is estimated to increase for the study period (2018–2030).


The United States Market Outlook

This section provides a total of Myocardial Infraction (MI) market size and market size by therapies in the United States.


The United States accounts for the highest Myocardial Infarction market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Myocardial Infraction (MI) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Myocardial Infraction (MI) market size and market size by therapies in Japan are also mentioned.

Myocardial Infraction (MI) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Myocardial Infraction (MI) market uptake by drugs; patient uptake by therapies; and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Myocardial Infraction (MI) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Myocardial Infraction (MI) key players involved in developing targeted therapeutics.


Major players include Empagliflozin (Boehringer Ingelheim/ Eli Lilly and Company) and CardiAMP Cell Therapy (Biocardia) being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Myocardial Infraction (MI) emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Myocardial Infraction (MI) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Myocardial Infraction (MI) market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Myocardial Infraction (MI) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Myocardial Infraction (MI), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Myocardial Infraction (MI) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Myocardial Infraction (MI) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Myocardial Infraction (MI) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Myocardial Infraction (MI) market

Report Highlights

  • In the coming years, Myocardial Infraction (MI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Myocardial Infraction (MI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Myocardial Infraction. The launch of emerging therapies will significantly impact the Myocardial Infraction (MI)market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Myocardial Infraction.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Myocardial Infraction (MI) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Myocardial Infraction (MI) Pipeline Analysis
  • Myocardial Infraction (MI) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Myocardial Infraction (MI) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Myocardial Infraction (MI) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Myocardial Infraction (MI) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Myocardial Infraction (MI) Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Myocardial Infraction (MI) total market Size as well as market Size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the market's key findings across 7MM and which country will have the largest Myocardial Infraction (MI) market Size during the forecast period (2018–2030)?
  • At what CAGR, the Myocardial Infraction (MI) market is expected to grow by 7MM during the forecast period (2018–2030)?
  • What would be the Myocardial Infraction (MI) market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Myocardial Infraction (MI) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Myocardial Infraction (MI)?
  • What is the historical Myocardial Infraction (MI) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of Myocardial Infraction (MI) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Myocardial Infraction (MI)?
  • Out of all 7MM countries, which country would have the highest Prevalent population of Myocardial Infraction (MI) during the forecast period (2018–2030)?
  • At what CAGR the population is expected to grow by 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Myocardial Infraction (MI)?
  • What are the current treatment guidelines for treating Myocardial Infraction (MI) in the USA, Europe, and Japan?
  • What are the Myocardial Infraction (MI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Myocardial Infraction (MI)?
  • How many therapies are developed by each company for the treatment of Myocardial Infraction (MI)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Myocardial Infraction (MI)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myocardial Infraction (MI) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myocardial Infraction (MI) and their status?
  • What are the key designations that have been granted for the emerging therapies for Myocardial Infraction (MI)?
  • What are the global historical and forecasted market of Myocardial Infraction (MI)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Myocardial Infraction (MI) market
  • To understand the future market competition in the Myocardial Infraction (MI) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Myocardial Infraction (MI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Myocardial Infraction (MI) market
  • To understand the future market competition in the Myocardial Infraction (MI) market

1. Key Insights

2. Report Introduction

3. Executive Summary of Myocardial Infarction (MI)

4. Myocardial Infarction Market Overview at a Glance

4.1. Market Share (%) Distribution of Myocardial Infarction in 2018

4.2. Market Share (%) Distribution of Myocardial Infarction in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. Risk Factors

5.3. Pathophysiology

5.4. Clinical Classification of Myocardial Infarction

5.4.1. Type 1

5.4.2. Type 2

5.4.3. Type 2 and myocardial injury

5.4.4. Type 3

5.4.5. Type 4a: Myocardial Infarction Associated With Percutaneous Coronary Intervention

5.4.6. Type 4b: Stent/Scaffold Thrombosis Associated With Percutaneous Coronary Intervention

5.4.7. Type 4c: Restenosis Associated With Percutaneous Coronary Intervention

5.4.8. Type 5: Myocardial Infarction Associated With Coronary Artery Bypass Grafting

5.5. Diagnosis

5.6. Biomarkers

5.6.1. Biomarkers Originated From Myocardial Tissues

5.6.2. Biomarkers Induced by Myocardial Infarction Incidence

5.6.3. Biomarkers Preexisted Before Myocardial Infarction Occurred

5.7. Definition of a Prior Myocardial Infraction

5.7.1. Recurrent Myocardial Infraction

5.7.2. Reinfarction

5.7.3. Peri-procedural Myocardial Infraction

5.8. WHO definition and diagnostic criteria of Myocardial Infraction

5.8.1. Category A definition and Diagnostic Criteria of Myocardial Infraction

5.8.2. Category B definition and diagnostic criteria of Myocardial Infarction if the requirements for diagnostic tests in Category A (above) Have Not Been Met

5.8.3. Category C definition and diagnostic criteria of probable Myocardial Infraction

5.8.4. Fourth Universal Definition of Myocardial Infarction

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Myocardial Infarction

6.3. Assumption and Rationale

7. The United States

7.1. Prevalent Cases of Myocardial Infarction in the United States

7.2. Gender-specific Prevalence of Myocardial Infarction in the United States

7.3. Type-specific Prevalence of Myocardial Infarction in the United States

8. EU5

8.1. Germany

8.1.1. Prevalent Cases of Myocardial Infarction in Germany

8.1.2. Gender-specific Prevalence of Myocardial Infarction in Germany

8.1.3. Type-specific Prevalence of Myocardial Infarction in Germany

8.2. France

8.2.1. Prevalent Cases of Myocardial Infarction in France

8.2.2. Gender-specific Prevalence of Myocardial Infarction in France

8.2.3. Type-specific Prevalence of Myocardial Infarction in France

8.3. Italy

8.3.1. Prevalent Cases of Myocardial Infarction in Italy

8.3.2. Gender-specific Prevalence of Myocardial Infarction in Italy

8.3.3. Type-specific Prevalence of Myocardial Infarction in Italy

8.4. Spain

8.4.1. Prevalent Cases of Myocardial Infarction in Spain

8.4.2. Gender-specific Prevalence of Myocardial Infarction in Spain

8.4.3. Type-specific Prevalence of Myocardial Infarction in Spain

8.5. United Kingdom

8.5.1. Prevalent Cases of Myocardial Infarction in the United Kingdom

8.5.2. Gender-specific Prevalence of Myocardial Infarction in the United Kingdom

8.5.3. Type-specific Prevalence of Myocardial Infarction in the United Kingdom

9. Japan

9.1. Prevalent Cases of Myocardial Infarction in Japan

9.2. Gender-specific Prevalence of Myocardial Infarction in Japan

9.3. Type-specific Prevalence of Myocardial Infarction in Japan

10. Treatment and Management

10.1. Antiplatelet agents

10.2. Anticoagulant agents

11. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation 2017

11.1. Evidenced-based Recommendations from the Guidelines

12. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

13. Marketed Therapies

13.1. Inspra: Pfizer

13.1.1. Product Description

13.1.2. Mechanism of action

13.1.3. Regulatory Milestones

13.1.4. Safety and Efficacy

13.1.5. Product Profile

13.2. Plavix: Sanofi-Aventis/Bristol-Myers Squibb

13.2.1. Product Description

13.2.2. Mechanism of action

13.2.3. Regulatory Milestones

13.2.4. Other Developmental Activities

13.2.5. Safety and Efficacy

13.2.6. Product Profile

13.3. Brilinta: AstraZeneca

13.3.1. Product Description

13.3.2. Mechanism of action

13.3.3. Regulatory Milestones

13.3.4. Safety and Efficacy

13.3.5. Product Profile

13.4. Zontivity: Merck

13.4.1. Product Description

13.4.2. Mechanism of action

13.4.3. Regulatory Milestones

13.4.4. Safety and Efficacy

13.4.5. Product Profile

13.5. Effient: Eli Lilly and Company/Daiichi Sankyo Co.

13.5.1. Product Description

13.5.2. Mechanism of action

13.5.3. Regulatory Milestones

13.5.4. Other Development Activity

13.5.5. Safety and Efficacy

13.5.6. Product Profile

13.6. Atacand: AstraZeneca/Takeda

13.6.1. Product Description

13.6.2. Mechanism of action

13.6.3. Regulatory Milestones

13.6.4. Product Profile

13.7. Diovan: Novartis

13.7.1. Product Description

13.7.2. Mechanism of action

13.7.3. Regulatory Milestones

13.7.4. Safety and Efficacy

13.7.5. Product Profile

13.8. TNKase: Genentech

13.8.1. Product Description

13.8.2. Mechanism of action

13.8.3. Regulatory Milestones

13.8.4. Other development Activity

13.8.5. Safety and Efficacy

13.8.6. Product Profile

13.9. Repatha: Amgen

13.9.1. Product Description

13.9.2. Mechanism of action

13.9.3. Regulatory Milestones

13.9.4. Safety and Efficacy

13.9.5. Product Profile

13.10. Praluent: Sanofi

13.10.1. Product Description

13.10.2. Mechanism of action

13.10.3. Regulatory Milestones

13.10.4. Other Development Activity

13.10.5. Safety and Efficacy

13.10.6. Product Profile

14. Emerging Therapies

14.1. Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company

14.1.1. Drug Description

14.1.2. Other Development activities

14.1.3. Clinical Development

14.1.4. Clinical Trials Information

14.1.5. Product Profile

14.2. CardiAMP cell therapy: Biocardia

14.2.1. Drug Description

14.2.2. Clinical Development

14.2.3. Clinical Trials Information

14.2.4. Product Profile

14.3. TQJ230: Novartis

14.3.1. Drug Description

14.3.2. Other Development Activities

14.3.3. Clinical Development

14.3.4. Clinical Trials Information

14.3.5. Product Profile

14.4. FDY 5301: Faraday Pharma

14.4.1. Drug Description

14.4.2. Clinical Development

14.4.3. Clinical Trials Information

14.4.4. Safety and Efficacy

14.4.5. Product Profile

14.5. CSL112: CSL Behring

14.5.1. Drug Description

14.5.2. Clinical Development

14.5.3. Clinical Trials Information

14.5.4. Safety and Efficacy

14.5.5. Product Profile

14.6. Farxiga: AstraZeneca

14.6.1. Drug Description

14.6.2. Other Development Activities

14.6.3. Clinical Development

14.6.4. Clinical Trials Information

14.6.5. Safety and Efficacy

14.6.6. Product Profile

14.7. Selatogrel: Idorsia

14.7.1. Drug Description

14.7.2. Other Development Activity

14.7.3. Clinical Development

14.7.4. Clinical Trials Information

14.7.5. Safety and Efficacy

14.7.6. Product Profile

15. Myocardial Infarction: 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size of Myocardial Infarction in 7MM

15.3. Market Size of Myocardial Infarction by Current Therapies

15.4. Market Size of Myocardial Infarction by Emerging Therapies

16. Market Outlook

16.1. United States Market Size

16.1.1. Total Market Size of Myocardial Infarction in United States

16.1.2. Market Size of Myocardial Infarction by Current Therapies in United States

16.1.3. Market Size of Myocardial Infarction by Emerging Therapies in United States

16.2. EU-5 Market Size

16.3. Germany

16.3.1. Total Market size of Myocardial Infarction in Germany

16.3.2. Market Size of Myocardial Infarction of Current Therapies in Germany

16.3.3. Market Size of Myocardial Infarction of Emerging Therapies in Germany

16.4. France

16.4.1. Total Market size of Myocardial Infarction in France

16.4.2. Market Size of Myocardial Infarction of current Therapies in France

16.4.3. Market Size of Myocardial Infarction of Emerging Therapies in France

16.5. Italy

16.5.1. Total Market size of Myocardial Infarction in Italy

16.5.2. Market Size of Myocardial Infarction of current Therapies in Italy

16.5.3. Market Size of Myocardial Infarction of Emerging Therapies in Italy

16.6. Spain

16.6.1. Total Market size of Myocardial Infarction in Spain

16.6.2. Market Size of Myocardial Infarction of current Therapies in Spain

16.6.3. Market Size of Myocardial Infarction of Emerging Therapies in Spain

16.7. United Kingdom

16.7.1. Total Market size of Myocardial Infarction in United Kindgom

16.7.2. Market Size of Myocardial Infarction of current Therapies in United Kingdom

16.7.3. Market Size of Myocardial Infarction of Emerging Therapies in United Kingdom

16.8. Japan

16.8.1. Total Market size of Myocardial Infarction in Japan

16.8.2. Market Size of Myocardial Infarction of current Therapies in Japan

16.8.3. Market Size of Myocardial Infarction of Emerging Therapies in Japan

17. Organizations contributing towards Myocardial Infarction

18. Patient Journey

19. Case Reports

20. KOL Views

21. Market Drivers

22. Market Barriers

23. SWOT Analysis

24. Unmet Needs

25. Appendix

25.1. Bibliography

26. Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight

List of Table

Table 1: Summary of Myocardial Infarction, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Prevalent Patient Population of Myocardial Infarction in 7MM (2018–2030)

Table 3: Prevalent Cases of Myocardial Infarction in the United States (2018–2030)

Table 4: Gender-specific Prevalence of Myocardial Infarction in the United States (2018–2030)

Table 5: Type-specific Prevalence of Myocardial Infarction in the United States (2018–2030)

Table 6: Prevalent Cases of Myocardial Infarction in Germany (2018–2030)

Table 7: Gender-specific Prevalence of Myocardial Infarction in Germany (2018–2030)

Table 8: Type-specific Prevalence of Myocardial Infarction in Germany (2018–2030)

Table 9: Prevalent Cases of Myocardial Infarction in France (2018–2030)

Table 10: Gender-specific Prevalence of Myocardial Infarction in France (2018–2030)

Table 11: Type-specific Prevalence of Myocardial Infarction in France (2018–2030)

Table 12: Prevalent Cases of Myocardial Infarction in Italy (2018–2030)

Table 13: Gender-specific Prevalence of Myocardial Infarction in Italy (2018–2030)

Table 14: Type-specific Prevalence of Myocardial Infarction in Italy (2018–2030)

Table 15: Prevalent Cases of Myocardial Infarction in Spain (2018–2030)

Table 16: Gender-specific Prevalence of Myocardial Infarction in Spain (2018–2030)

Table 17: Type-specific Prevalence of Myocardial Infarction in Spain (2018–2030)

Table 18: Prevalent Cases of Myocardial Infarction in the United Kingdom (2018–2030)

Table 19: Gender-specific Prevalence of Myocardial Infarction in the United Kingdom (2018–2030)

Table 20: Type-specific Prevalence of Myocardial Infarction in the United Kingdom (2018–2030)

Table 21: Prevalent Cases of Myocardial Infarction in Japan (2018–2030)

Table 22: Gender-specific Prevalence of Myocardial Infarction in Japan (2018–2030)

Table 23: Type-specific Prevalence of Myocardial Infarction in Japan (2018–2030)

Table 24: Comparison of Anticoagulants Used to Treat Acute Coronary Syndrome

Table 25: Empagliflozin, Clinical Trial Description, 2021

Table 26: CardiAMP Cell therapy, Clinical Trial Description, 2021

Table 27: Pelacarsen, Clinical Trial Description, 2021

Table 28: FDY-5301, Clinical Trial Description, 2021

Table 29: CSL112, Clinical Trial Description, 2021

Table 30: Farxiga, Clinical Trial Description, 2021

Table 31: Selatogrel, Clinical Trial Description, 2021

Table 32: 7 Major Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 33: United States Market Size of Myocardial Infarction by Current Therapies in USD Million (2018–2030)

Table 34: United States Market Size of Myocardial Infarction by Emerging Therapies in USD Million (2018–2030)

Table 35: United States Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 36: United States Market Size of Myocardial Infarction of Current Therapies in USD Million (2018–2030)

Table 37: United States Market Size of Myocardial Infarction by Emerging Therapies in USD Million (2018–2030)

Table 38: Germany Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 39: Germany Market Size of Myocardial Infarction of Current Therapies in USD Million (2018–2030)

Table 40: Germany Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Table 41: France Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 42: France Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Table 43: France Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Table 44: Italy Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 45: Italy Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Table 46: Italy Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Table 47: Spain Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 48: Spain Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Table 49: Spain Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Table 50: United Kingdom Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 51:  UK Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Table 52:  UK Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Table 53: Japan Market Size of Myocardial Infarction in USD Million (2018–2030)

Table 54: Japan Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Table 55: Japan Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Table 56: Organizations contributing towards Myocardial Infarction

List of Figures

Figure 1: Framework for Type 2 Myocardial Infarction Considering the Clinical Context and Pathophysiological Mechanisms Attributable to Acute Myocardial Ischemia

Figure 2: A Model for Interpreting Myocardial Injury

Figure 3: Diagnostic Algorithm for Myocardial Infarction With Non-obstructive Coronary Arteries Using a Traffic Light

Figure 4: Prevalent Patient Population of Myocardial Infarction in 7MM (2018–2030)

Figure 5: Prevalent Cases of Myocardial Infarction in the United States (2018–2030)

Figure 6: Gender-specific Prevalence of Myocardial Infarction in the US (2018–2030)

Figure 7: Type-specific Prevalence of Myocardial Infarction in the United States (2018–2030)

Figure 8: Prevalent Cases of Myocardial Infarction in Germany (2018–2030)

Figure 9: Gender-specific Prevalence of Myocardial Infarction in Germany (2018–2030)

Figure 10: Type-specific Prevalence of Myocardial Infarction in Germany (2018–2030)

Figure 11: Prevalent Cases of Myocardial Infarction in France (2018–2030)

Figure 12: Gender-specific Prevalence of Myocardial Infarction in France (2018–2030)

Figure 13: Type-specific Prevalence of Myocardial Infarction in France (2018–2030)

Figure 14: Prevalent Cases of Myocardial Infarction in Italy (2018–2030)

Figure 15: Gender-specific Prevalence of Myocardial Infarction in Italy (2018–2030)

Figure 16: Type-specific Prevalence of Myocardial Infarction in Italy (2018–2030)

Figure 17: Prevalent Cases of Myocardial Infarction in Spain (2018–2030)

Figure 18: Gender-specific Prevalence of Myocardial Infarction in Spain (2018–2030)

Figure 19: Type-specific Prevalence of Myocardial Infarction in Spain (2018–2030)

Figure 20: Prevalent Cases of Myocardial Infarction in the United Kingdom (2018–2030)

Figure 21: Gender-specific Prevalence of Myocardial Infarction in the United Kingdom (2018–2030)

Figure 22: Type-specific Prevalence of Myocardial Infarction in the United Kingdom (2018–2030)

Figure 23: Prevalent Cases of Myocardial Infarction in Japan (2018–2030)

Figure 24: Gender-specific Prevalence of Myocardial Infarction in Japan (2018–2030)

Figure 25: Type-specific Prevalence of Myocardial Infarction in Japan (2018–2030)

Figure 26: Common complications following acute myocardial infarction and their approximate timing

Figure 27: 7 Major Market Size of Myocardial Infarction in USD Million (2018–2030)

Figure 28: 7 Major Market Size of Myocardial Infarction by Current Therapies in USD Million (2018–2030)

Figure 29: 7 Major Market Size of Myocardial Infarction by Emerging Therapies in USD Million (2018–2030)

Figure 30: Market Size of Myocardial Infarction in the United States, USD Million (2018–2030)

Figure 31: The United States Market Size of Myocardial Infarction by Current Therapies in USD Million (2018–2030)

Figure 32: The United States Market Size of Myocardial Infarction by Emerging therapies Therapies in USD Million (2018–2030)

Figure 33: Market Size of Myocardial Infarction in the Germany, USD Million (2018–2030)

Figure 34: The Germany Market Size of Myocardial Infarction of Current Therapies in USD Million (2018–2030)

Figure 35: The Germany Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Figure 36: Market Size of Myocardial Infarction in the France, USD Million (2018–2030)

Figure 37: The France Market Size of Myocardial Infarction of current Therapies in USD Million

Figure 38: The France Market Size of Myocardial Infarction of Emerging Therapies in USD Million

Figure 39: Market Size of Myocardial Infarction in the Italy, USD Million (2018–2030)

Figure 40: The Italy Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Figure 41: The Italy Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Figure 42: Market Size of Myocardial Infarction in the Spain, USD Million (2018–2030)

Figure 43: The Spain Market Size of Myocardial Infarction of current Therapies in USD Million

Figure 44: The Spain Market Size of Myocardial Infarction of Emerging Therapies in USD Million

Figure 45: Market Size of Myocardial Infarction in the United Kingdom, USD Million (2018–2030)

Figure 46: The United Kingdom Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Figure 47: The United Kingdom Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

Figure 48: Market Size of Myocardial Infarction in the Japan, USD Million (2018–2030)

Figure 49: The Japan Market Size of Myocardial Infarction of current Therapies in USD Million (2018–2030)

Figure 50: The Japan Market Size of Myocardial Infarction of Emerging Therapies in USD Million (2018–2030)

• Pfizer

• Sanofi-Aventis/Bristol-Myers Squibb

• AstraZeneca

• Merck

• Eli Lilly and Company/Daiichi Sankyo Co.

• AstraZeneca/Takeda

• Novartis

• Genentech

• Amgen

• Sanofi

• Boehringer Ingelheim/Eli Lilly and Company

• Biocardia

• Novartis

• Faraday Pharma

• CSL Behring

• AstraZeneca

• Idorsia

  • Tags:
  • Myocardial Infarction market
  • Myocardial Infarction market resea...
  • Myocardial Infarction market insig...
  • Myocardial Infarction market trend...
  • Myocardial Infarction market forec...
  • Myocardial Infarction market share
  • Myocardial Infarction pipeline dru...
  • Myocardial Infarction treatment al...
  • Myocardial Infarction drugs
  • Myocardial Infarction sales foreca...
  • Myocardial Infarction market size
  • Myocardial Infarction disease
  • Myocardial Infarction epidemiology
  • Myocardial Infarction 

Forward to Friend

Need A Quote